Patents by Inventor Django Sussman

Django Sussman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD33 antibodies and use of same to treat cancer
    Patent number: 9587019
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: March 7, 2017
    Assignee: SEATTLE GENETICS, INC.
    Inventors: May Kung Sutherland, Maureen Ryan, Django Sussman, Patrick Burke, Scott Jeffrey
  • VARIANT TARGET BINDING AGENTS AND USES THEREOF
    Publication number: 20160367697
    Abstract: The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.
    Type: Application
    Filed: June 22, 2016
    Publication date: December 22, 2016
    Inventors: Paul Carter, Django Sussman
  • Humanized Antibodies To LIV-1 And Use Of Same To Treat Cancer
    Publication number: 20160185858
    Abstract: The invention provides humanized antibodies that specifically bind to LIV-1. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting LIV-1.
    Type: Application
    Filed: November 20, 2015
    Publication date: June 30, 2016
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Maria Leia Smith, Django Sussman, William Arthur, Albina Nesterova
  • Humanized antibodies to LIV-1 and use of same to treat cancer
    Patent number: 9228026
    Abstract: The invention provides humanized antibodies that specifically bind to LIV-1. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting LIV-1.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: January 5, 2016
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Maria Leia Smith, Django Sussman, William Arthur, Albina Nesterova
  • METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION
    Publication number: 20150337259
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Application
    Filed: February 26, 2015
    Publication date: November 26, 2015
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Variant target binding agents and uses thereof
    Patent number: 9061074
    Abstract: The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 23, 2015
    Assignee: Seattle Genetics, Inc.
    Inventors: Paul Carter, Django Sussman
  • CD33 ANTIBODIES AND USE OF SAME TO TREAT CANCER
    Publication number: 20150147316
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.
    Type: Application
    Filed: May 15, 2013
    Publication date: May 28, 2015
    Applicant: SEATTLE GENETICS, INC.
    Inventors: May Kung Sutherland, Maureen Ryan, Django Sussman, Patrick Burke, Scott Jeffrey
  • Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
    Patent number: 8993326
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: March 31, 2015
    Assignee: Seattle Genetics, Inc.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION
    Publication number: 20140031536
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Application
    Filed: October 1, 2013
    Publication date: January 30, 2014
    Applicant: Seattle Genetics, Inc.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • CD33 Antibodies And Use Of Same To Treat Cancer
    Publication number: 20130309223
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.
    Type: Application
    Filed: March 14, 2013
    Publication date: November 21, 2013
    Inventors: MAY KUNG SUTHERLAND, MAUREEN RYAN, DJANGO SUSSMAN, PATRICK BURKE, SCOTT JEFFREY
  • Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
    Patent number: 8574907
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: November 5, 2013
    Assignee: Seattle Genetics, Inc.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Humanized Antibodies To LIV-1 And Use Of Same To Treat Cancer
    Publication number: 20130259860
    Abstract: The invention provides humanized antibodies that specifically bind to LIV-1. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting LIV-1.
    Type: Application
    Filed: December 6, 2011
    Publication date: October 3, 2013
    Inventors: Maria Leia Smith, Django Sussman, William Arthur, Albina Nesterova
  • Variant target binding agents and uses thereof
    Patent number: 8455622
    Abstract: The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.
    Type: Grant
    Filed: December 1, 2007
    Date of Patent: June 4, 2013
    Assignee: Seattle Genetics, Inc.
    Inventors: Charlotte McDonagh, Paul Carter, Django Sussman
  • METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION
    Publication number: 20120183997
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Application
    Filed: February 24, 2012
    Publication date: July 19, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: STEPHEN C. ALLEY, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
    Patent number: 8163551
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: April 24, 2012
    Assignee: Seattle Genetics, Inc.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Variant Target Binding Agents and Uses Thereof
    Publication number: 20100158909
    Abstract: The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.
    Type: Application
    Filed: December 1, 2007
    Publication date: June 24, 2010
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Charlotte McDonagh, Paul Carter, Django Sussman
  • METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION
    Publication number: 20090317869
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Application
    Filed: May 1, 2009
    Publication date: December 24, 2009
    Applicant: Seattle Genetics, Inc.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke